eCite Digital Repository

Genetic variation in PEAR1, cardiovascular outcomes and effects of aspirin in a healthy elderly population

Citation

Lewis, JP and Riaz, M and Xie, S and Polekhina, G and Wolfe, R and Nelson, M and Tonkin, AM and Reid, CM and Murray, AM and McNeil, JJ and Shuldiner, AR and Lacaze, P, Genetic variation in PEAR1, cardiovascular outcomes and effects of aspirin in a healthy elderly population, Clinical Pharmacology and Therapeutics, 108, (6) pp. 1289-1298. ISSN 0009-9236 (2020) [Refereed Article]


Preview
PDF (final author version)
11Mb
  

Copyright Statement

2020 American Society for Clinical Pharmacology and Therapeutics

DOI: doi:10.1002/cpt.1959

Abstract

The platelet endothelial aggregation receptor-1 (PEAR1) rs12041331 variant has been identified as a genetic determinant of platelet aggregation in response to antiplatelet therapies, including aspirin. However, association with atherothrombotic cardiovascular events is less clear, with limited evidence from large trials. Here, we tested association of rs12041331 with cardiovascular events and aspirin use in a randomized trial population of healthy older individuals. We undertook post-hoc analysis of N=13,547 participants of the ASPirin in Reducing Events in the Elderly (ASPREE) trial, median age 74 years. Participants had no previous diagnosis of atherothrombotic cardiovascular disease at enrolment, and were randomized to either 100 mg daily low-dose aspirin or placebo for median 4.7 years follow-up. We used Cox proportional hazard regression to model the relationship between rs12041331 and the ASPREE primary cardiovascular disease endpoint (CVD), and composites of major adverse cardiovascular events (MACE) and ischaemic stroke (STROKE); and bleeding events; major hemorrhage (MHEM) and intracranial bleeding (ICB). We performed whole-population analysis using additive and dominant inheritance models, then stratified by treatment group. Interaction effects between genotypes and treatment group were examined. We observed no statistically significant association (P<0.05) in the population, or by treatment group, between rs12041331 and cardiovascular or bleeding events in either model. We also found no significant interaction effects between rs12041331-A and treatment group, for CVD (P=0.65), MACE (P=0.32), STROKE (P=0.56), MHEM (P=0.59) or ICB (P=0.56). The genetic variant PEAR1 rs12041331 is not associated with cardiovascular events in response to low-dose aspirin in a healthy elderly population.

Item Details

Item Type:Refereed Article
Keywords:genetics, aspirin, platelet aggregation, cardiovascular disease
Research Division:Biomedical and Clinical Sciences
Research Group:Cardiovascular medicine and haematology
Research Field:Cardiology (incl. cardiovascular diseases)
Objective Division:Health
Objective Group:Clinical health
Objective Field:Clinical health not elsewhere classified
UTAS Author:Nelson, M (Professor Mark Nelson)
ID Code:139932
Year Published:2020
Web of Science® Times Cited:4
Deposited By:Menzies Institute for Medical Research
Deposited On:2020-07-16
Last Modified:2021-03-26
Downloads:0

Repository Staff Only: item control page